Mylan Pharmaceuticals Inc. v. Acorda Therapeutics Inc.

Petition for certiorari denied on January 9, 0017

Docket No.	Op. Below	Argument	Opinion	Vote	Author	Term
16-360	Fed. Cir.	N/A	N/A	N/A	N/A	OT 16

Issue: Whether the mere filing of an abbreviated new drug application by a generic pharmaceutical manufacturer is sufficient to subject the manufacturer to specific personal jurisdiction in any state where it might someday market the drug.

SCOTUSblog Coverage

Petition of the day (Kate Howard, October 19, 2016)

Date	Proceedings and Orders (key to color coding)
09/19/2016	Petition for a writ of certiorari filed. (Response due October 21, 2016)
10/04/2016	Consent to the filing of amicus curiae briefs, in support of either party or of neither party, received from counsel for the respondents Acorda Therapeutics, Inc., and Pharma Ireland Limited.
10/06/2016	Order extending time to file response to petition to and including November 21, 2016, for all respondents.
10/21/2016	Brief amicus curiae of Generic Pharmaceutical Association filed.
11/21/2016	Brief of respondent AstraZeneca AB in opposition filed.
11/21/2016	Brief of respondents Acorda Therapeutics, Inc. and Alkermes Pharma Ireland Limited in opposition filed.
12/07/2016	DISTRIBUTED for Conference of January 6, 2017.
12/07/2016	Reply of petitioners Mylan Pharmaceuticals, et al. filed. (Distributed)
12/12/2016	Rescheduled.
12/21/2016	DISTRIBUTED for Conference of January 6, 2017.
01/09/2017	Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.